Cellares and Sonoma Biotherapeutics agreed to automate the manufacturing of SBT-77-7101, an engineered regulatory T cell therapy in phase I for poly-refractory rheumatoid arthritis. Cellares will translate SonomaBio’s manufacturing process to its Cell Shuttle, and automate in-process and release testing through the Cell Q quality control system tied to its Smart Factory infrastructure.